Bajaj Healthcare Ltd. a leading manufacturer of APIs, Intermediates and Formulations, Ltd has announced that it has entered into a definitive CDMO agreement with esteemed UK/EU based customers for the supply of 15 Active Pharmaceutical Ingredient (APIs). 

Under this agreement, BHL will undertake the development and supply of these molecules, which will be exclusively manufactured for its clientele. These APIs encompass a diverse range of compounds, including off-patent generics and molecules soon to be off-patent. The CDMO agreement will be executed through its in-house R&D and manufacturing capacities at Savli Vadodara, Gujarat. 

Commenting on the above business update, Anil Jain, Joint Managing Director, Bajaj Healthcare said: "I am thrilled to share this strategic collaboration which underscores Bajaj Healthcare Ltd.'s commitment to innovation, excellence, and meeting the evolving needs of the pharmaceutical industry. By harnessing our expertise and state-of-the-art infrastructure, we are poised to enhance the accessibility and affordability of essential medications for patients across the globe. Leveraging our cutting-edge in-house Research and Development (R&D) facilities and manufacturing capabilities located at Savli, BHL is poised to deliver exceptional quality and efficiency in meeting our customers' requirements.